|
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Forest Laboratories |
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00586066 |
The purpose of this study is to see whether Memantine improves memory function in subjects with bipolar disorder who have minimal symptoms. Secondary analyses will test the role of Memantine in improving residual mood symptoms (depression and mania) in subjects with bipolar disorder.
We hypothesize that in subjects with bipolar disorder who have minimal symptoms Memantine will be effective in improving cognitive functions, as measured by the difference in neuropsychological test scores at the beginning and at the end of the trial.
Condition | Intervention | Phase |
Bipolar Disorder |
Drug: Memantine |
Phase IV |
MedlinePlus related topics: | Bipolar Disorder |
ChemIDplus related topics: | Memantine Memantine hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Memantine and Cognitive Dysfunction in Bipolar Disorder |
Estimated Enrollment: | 75 |
Study Start Date: | November 2005 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Placebo Comparator |
Drug: Memantine
Week 0 - 5mg Memantine or placebo q.d. Week 1 - 5mg Memantine or placebo b.i.d. Week 2-3 - 5mg Memantine or placebo q.a.m./10mg q.p.m. Week 4-12 - 10mg Memantine or placebo b.i.d.
|
A large proportion of subjects with bipolar disorder experience significant cognitive dysfunction, even when euthymic, after adequate treatment. The cognitive deficits in asymptomatic patients with bipolar disorder are very important for the subject's psychosocial function. In this population, cognitive deficits have been associated with poor psychosocial functioning, such as inability to hold a job. Memantine is a glutamate NMDA receptor antagonist which has shown efficacy in cognitive dysfunction due to moderate to severe Alzheimer disease.
Demonstrating the role of Memantine in reducing cognitive dysfunction in minimally symptomatic subjects with bipolar disorder promises to provide important clinical information, which could lead to improvements in well-being and functional status for large populations of subjects with bipolar disorder.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients meeting any of the following criteria will be excluded from the study:
Contact: Rebecca M. Ametrano, B.A. | 617-726-0997 | rametrano@partners.org |
Contact: Claire A. Tilley, B.A. | 617-726-7591 | catilley@partners.org |
United States, California | |||||
Cedars Sinai Department of Psychiatry | Recruiting | ||||
Los Angeles, California, United States, 90048 | |||||
Contact: Lana Levi, B.A. 310-423-0744 lana.levi@cshs.org | |||||
Principal Investigator: Mark Rappaport, M.D. | |||||
United States, Illinois | |||||
Asher Depression Center, Northwestern University | Recruiting | ||||
Chicago, Illinois, United States, 60611 | |||||
Contact: Jordana Segal, Psy.D. 312-695-2203 j-segal@northwestern.edu | |||||
Principal Investigator: William Gilmer, M.D. | |||||
United States, Massachusetts | |||||
Massachusetts General Hospital | Recruiting | ||||
Boston, Massachusetts, United States, 02114 | |||||
Contact: Rebecca M. Ametrano, B.A. 617-726-0997 rametrano@partners.org | |||||
Contact: Claire A. Tilley, B.A. 617-726-7591 catilley@partners.org | |||||
Principal Investigator: Andrew A. Nierenberg, M.D. | |||||
Sub-Investigator: Dan V. Iosifescu, M.D. | |||||
Sub-Investigator: Thilo Deckersbach, Ph.D. |
Massachusetts General Hospital |
Forest Laboratories |
Principal Investigator: | Andrew A. Nierenberg, M.D. | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( Andrew A. Nierenberg, M.D., Professor of Psychiatry, Harvard Medical School ) |
Study ID Numbers: | 2005-p-001651 |
First Received: | December 21, 2007 |
Last Updated: | December 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00586066 |
Health Authority: | United States: Federal Government |
|
|
|
|
|